Skin substitutes composed of cultured cells and biopolymers provide alternative materials for study of skin biology and pathology, treatment of skin wounds, safety testing of consumer products, and therapeutic delivery of gene products. Most frequently, substitutes for epidermis consist of cultured keratinocytes and dermal substitutes consist of resorbable biopolymers populated with cultured fibroblasts. Preclinical models characterize cellular morphogenesis, antigen expression, and barrier properties in vitro, and recovery of tissue function after grafting. Clinical considerations include time required to prepare cultured autografts, time required for graft vascularization, management of microbial contamination in wounds, mechanical fragility of cultured grafts, and high cost. Safety in graft preparation generally requires the use of materials and procedures that comply with standards for quality assurance. Efficacy of engineered skin substitutes has been evaluated predominantly by subjective criteria, but evaluation may become more objective and quantitative by application of noninvasive biophysical instrumentation. Future directions with engineered skin substitutes are expected to include gene therapy by addition or deletion of selected gene products and establishment of international standards for fabrication and assessment of engineered skin.
DESIGN CONSIDERATIONS
Design of cultured skin substitutes must address the following categories of considerations: Basic design considerations for an "artificial skin" have been described to include control of infection, fluid loss, contracture, and scarring.14 These requirements are part of a larger set of requirements for temporary and permanent skin substitutes that include rapid adherence and vascularization, mechanical stability and durability, and cost-effectiveness. 15 Restoration of skin anatomy should include not only epidermis and dermis, but also skin pigmentation, nerve, vascular plexus, and adnexa (glands, follicles). Although reasonable analogues of epidermal skin have been d e~e l o p e d '~'~ and skin pigmentation has been restored clinically by transplantation of cultured m e l a n o~y t e s ,~~ most skin substitutes do not contain biopolymers with native molecular structure. Studies to include nerve, blood vessels, and glands remain in preliminary stages of e~p e r i m e n t a t i o n .~~,~~ Cells for preparation of skin substitutes may be propagated from autologous or allogeneic tissues. Autologous cells can be ~ermanent?~ but they require 3-4 weeks to propagate in sufficient numbers to transplant therapeutically. Conversely, allogeneic cells have been shown to persist only temporarily but provide virtually unlimited a~ailability.~~ In general, these cell sources serve, respectively, acute wounds (i.e., bums, trauma), and chronic wounds (cutaneous ulcers). 25 An exciting potential for improved utilization of autologous cells is preparation of cultured skin from chimeric cell populations. Although this approach has been demonstrated in preclinical s t~d i e s ,~~,~~ clinical studies with chimeric grafts are not yet reported. However, feasibility for clinical use of chimeric grafts is supported strongly by the well-established use of combined autologous and allogeneic skin grafts28 if donor autograft has limited availability.
Biopolymers for cultured skin substitutes may be tissue derived or s y r~t h e t i c .~~-~~ Collagen is commonly used in medical devices as an implant or a coating onto which cells can attach and migrate during healing. Medical grades of collagen range in nativity from low, as in gelatin sponges?3 to high, as in decellularized cadaver dermis. 34 In general, nativity of collagen structure delays degradation. Other natural biopolymers of increasing importance are hyaluronic acid,35 which has been associated with scarless wound healing in the fetus?6 and fibrin.37 By comparison, synthetic polymers (i.e., polylactic acid [PLA] and polygalactic acid [PGA]) have become standard for certain medical applications including suturing and repair of the abdominal wall. Fabric made from PLAfPGA has been studied as a vehicle for delivery of skin cells but was associated with extrusion of the polymer from the wound.38 Microbial contamination of PGA/PLA grafts has been reported to be lower than with collagenous implants,39 but cell survival of transplanted cells is also reduced. These results suggest that release of acidic monomers during hydrolytic degradation of the polymer may generate a sufficiently acidic pH to be cytotoxic.
As engineered tissues become more sophisticated, cost and complexity of fabrication also increase. Although these factors are sometimes discounted, complexity of fabrication should be considered initially, if engineered tissues are to be made practical. Fibroblast-populated collagen gels with cultured keratinocytes19 have been demonstrated to generate analogues of skin with good histologic fidelity to skin. Although allogeneic forms of this model have been used to treat chronic wounds, it has not been practical for preparation with autologous cells because of the long maturation periods during fabrication.
Essential to availability of tissue-engineered skin is technology for storage or banking of individual and composite materials. In general, hydrated materials (cells, biopolymers) must be cryopreserved for longterm storageM or dehydrated chemically or physically34 to reduce rates of decomposition. Mammalian cells do not survive drying, but acellular materials are most often stored dry after desiccation by freeze-drying.34,41,42 Each of these storage techniques allows accumulation of materials for subsequent preparations or applications. Many principles and standards of storage of tissue and tissue-derived materials have been established by the practice of tissue banking and organ procurement for medical t r a n~p l a n t a t i o n .~~.~~ Although specific procedures for tissue storage remain variable from one institution to another, most of the principles and standards can be adapted directly for engineered tissues.
PRECLINICAL MODELS
Composition and performance of skin substitutes must be evaluated before initiation of clinical studies. Similar to other experimental therapies, cultured skin substitutes may be validated for function by evaluation in vitro and in animals. Factors to be evaluated include, but are not limited to, the following: For skin, epidermal keratinocytes are definitive for wound closure. Combination of cultured keratinocytes with an acellular biopolymer matrix16 probably constitutes the minimum essential requirement for definitive restoration of skin function. Fibroblasts have been incorporated into certain model^^^.^^ to promote reestablishment of epithelial-mesenchymal interactions that are r e~o~n i z e d~~.~~ but remain poorly understood. Addition of epidermal melanocytes to cultured skin in vitro has also been r e p~r t e d .~~.~~ As cellular complexity of engineered skin increases, formulation of media also becomes more complex. Although cells at high density are subject to the same requirements for essential nutrients as low-density culture~,5~ both rates of cellular metabolism and requirements for exogenous growth factors decrease generally as skin analogues form. 53 In cultured skin models, exposure of the epithelium to air also promotes formation of epidermal which may be considered "mophogenesis." Epidermal bamer has been measured quantitatively by transepidermal water 1 0 s s , 5~-~~ percutaneous absorption of chemicals and radio-isotope~?~,~~ surface electrical c a p a c i t a n~e ?~.~~ biochemical analysis of barrier-specific lipid^,^^,^^ and x-ray diffraction of stratum c o r n e~m .~~ Cultured keratinocyte sheet^'^.^^ cannot be evaluated for barrier properties in vitro because they are prepared in submerged culture. However, epidermal barrier function has been demonstrated transiently and at only 75-90% of values for native skin,55756763 and no other skin functions are recovered. Deficiencies in epidermal barrier have been associated with excessive accumulation of triglycerides in keratinocytes and very low levels of stratum corneum lipid^.^^,^^ These deficiencies are consistent with a hyperproliferative cellular phenotype. In most models, mechanical properties of skin substitutes in vitro are less than 10% of native skin. But, use of acellular dermal or fabrics of absorbable polymers (i.e., PLA/PGA)38,39 provides some elasticity and strength similar to native skin. Melanocytes have been shown to reside passively in skin s u b s t i t~t e s , "~,~~,~~ and measurement in vitro of pigment expression with the ~hromarneter~~ consistently shows less color than in the donor skin. Vascular plexus, nerves, glands, follicles, and immune effector cells are absent. Furthermore, the perishable nature of skin substitutes in vitro confirms the deficiencies of current culture systems.
After grafting in animal model^>^,^^ pigmentation varies from partial to ~o m p l e t e~~.~~ and adnexa do not reform. However, transplantation of cultured skin regenerates functional and stable barrier and repairs fibrovascular tissue. Because most models of skin substitutes are prepared with human cells and are xenografts, athymic mice have been used for long-term studies by several laboratorie~."~.~~*~~,~~ Grafting of autologous or allogeneic keratinocytes to immunocompetent pigs7' has been performed for short-term studies because pig skin is considered most similar to human skin in anatomy and physiology. Stable restoration of barrier function after grafting may be termed "histogenesis" because a definitive function of skin tissue is regained. Quantitative endpoints for these studies have included, but are not limited to, wound area,51v7* ordinal scoring of human cells and expression of specific proteins, mRNAs, and lipids.67,73,74 Particular attention has been given to detection and quantification of factors for angiogenesis and proliferation (i.e., basic fibroblast growth factor, transforming growth factors a and /3, platelet-derived growth factor, and insulin-like growth factors), inflammatory mediators (i.e., interleukins and arachidonic acid metabolites), and extracellular matrix components (i.e., collagens, polysaccharides, laminin, and kalinin) by transplanted ~e l l s .~~-~~ Together, the qualitative and quantitative proportions of cellular and extracellular factors define tissue integrity. Findings from these studies demonstrate consistently the following: that epithelium of skin substitutes is hyperproliferative and incompletely keratinized in vitro; that cell proliferation and epidermal bamer normalize after grafting; and that restoration of mechanical strength requires a dermal substitute. However, because the functions of glands, follicles, and nerve are not fully recovered, true "organogenesis" of skin has not yet been accomplished. Even grafts of native split-thickness skin do not contain adnexa because glands and follicles are generated only during development, not in wound healing. Therefore contemporary models of engineered skin are based on duplication in vitro of wound healing physiology, not developmental physiology.
Assessments of efficacy of cultured skin substitutes in preclinical models have certain strengths and limitations. Rates of engraftment and wound area can be determined with reasonable validity. But because rodents do not scar extensively, formation of keloid or hypertrophic scar cannot be evaluated well. However, recovery of skin function can be evaluated with biophysical instr~mentation?~ and molecular analysis can be performed in comparison to native human skin. Normalization of function (i.e., epidermal barrier) does not necessarily reflect normal metabolism (i.e., barrier lipid profiles).80 For these analyses preclinical models are very useful, but they are influenced by host metabolism that may introduce artifact in comparison to clinical performance of grafts.
CLINICAL CONSIDERATIONS
Anatomic and physiologic deficiencies in epidermal barrier and vascular supply confer on skin substitutes practical limitations that must be managed to accomplish efficacy of wound closure. Among these limitations are the following:
1. Mechanical fragility. 2. Susceptibility to microbial contamination. Early reports with clinical application of keratinocyte sheets proved the life-saving potential of cultured skin substitute^.^^,^^ These studies also identified multiple limitations to their routine use according to procedures for split-thickness skin. If grafted onto subcutaneous fat after excision of full-thickness bums, keratinocyte sheets attach poorly and are destroyed by mechanical shear and microbial contamination. To irnprove engraftment, proponents recommended during the 1980s excision to muscle fascia that resulted in removal of viable tissue and disfigurement. It was also noted that healed epithelium subsequently ulcerated and often required regrafting. These results increased rather than decreased time to completion of healing. In addition, the cost of preparation of keratinocyte sheets for large burns is extremely high. Later studies combined keratinocyte sheets with cadaveric allograft from which the allogeneic epidermis had been surgically removed.82 This approach has gained more common use, and is reported to have fewer complicat i o n~.~~ However, it requires availability of viable cadaveric allograft skin.
Combination of epidermal cells with dermal substitutes in vitro has been shown to virtually eliminate epidermal blistering after engraftment of transplanted keratinocyte~.~~ More rapid formation of basement membrane and anchoring fibril^^^,^^ in dermal-epidermal models may result from initiation of cell-substrate attachments in vitro and elimination of enzymatic release of cell sheets immediately before grafting. An important limitation of composite skin substitutes is lack of vascular supply in the dermal substitute. This limitation extends time for reperfusion, ischemia, and nutrient deprivation to transplanted cells that reduce rates of engraftment. Cell survival and engraftment may be improved significantly by irrigation of grafts with solutions of nutrients87 and noncytotoxic antimicrobial a g e n t~.~~-~O This approach optimizes the wound environment to promote survival of transplanted cells and manage microbial contamination until vascularization is complete.
The high cost of cultured skin substitutes remains a practical factor for clinical use. Estimates of cost of keratinocyte sheets range from $1,000 to $13,000 per percentage of body surface area c~v e r e d .~~.~~ Those costs can approximately double if a dermal substitute is also ~s e d .~~.~~ Therefore costs can become lirniting for treatment of large (60-90% of total body surface area) bums with cultured skin substitutes. At present, no studies have convincingly demonstrated a savings of total hospitalization costs by use of cultured skin substitutes of any kind. For contemporary treatment of burns, cultured skin substitutes remain an important adjunct to conventional skin grafting94 but are not a primary modality of wound closure except in extreme cases.
REGULATION AND ASSESSMENT
With appropriate management of clinical limitations, wound closure with cultured skin substitutes has been demonstrated for acute and chronic ~o~n d s .~.~~,~~,~~ Cultured skin substitutes are part of a spectrum of materials extending from cadaveric skin allograft to tissue-derived materials (keratinocyte sheets, dermal matrix), to specific combinations of cells and purified polymers. Because some kinds of skin substitutes, including cultured keratinocyte sheets, were considered initially a form of tissue banking, requirements for demonstration of efficacy were virtually absent.97 Conversely, cultured skin substitutes consisting of cultured cells attached to biodegradable polymers are currently regulated in the United States as class III (significant risk) medical devices with rigorous requirements for demonstration of safety and efficacy, and compliance with good manufacturing practices (GMPs).
Regulatory complexities among these materials have been recognized by the U.S. Food and Drug Administration (FDA) and the European Committee for Standardization (CEN). The FDA has responded by assembly of an Inter-Center Focus Group on Wound Healing to explore whether uniform standards for evaluation of safety and efficacy can be established for wound treatment materials.98 This ambitious goal may provide, at minimum, a set of reference endpoints and, at maximum, an absolute set of parameters and methods for evaluation of experimental therapies including tissue-engineered skin. Similarly, The CEN has established three directives pertaining to medical devices: the Medical Devices Directive, the Active Implantable Medical Devices Directive, and the In Vitro Diagnostic Medical Devices D i r e~t i v e .~~
The CEN adopted its directives in the 1990s as part of the process of harmonization within the emerging European Community. Many parallels exist between the FDA and CEN standards, for example, in classification of medical devices. As economic globalization proceeds, resources will be conserved if regulatory standards can be harmonized concurrently. The International Standards Organization has established regulations for control of sterility in product manufacture that overlap with standards for GMPs.'OO.'O1 Because the underlying factors for medical safety and efficacy supersede national citizenship, progressive globalization of standards for medical devices that include cultured cells may prospectively be addressed by the World Health Organization or similar affiliation of international experts. Current standards in the United States recognize generally that wound closure (reepithelialization) is an acceptable endpoint of wound healing with cultured skin substitutes. However, a distinction can readily be made between percentage of engraftment, and percentage of coverage of the body surface because in burns, percentage of engraftment of cultured skin is inversely related to magnitude of injury.lo2 Standardization of these kinds of endpoints and distinctions in assessment will benefit all patients who are treated with cultured skin substitutes.
Particular attention has been given to methods for noninvasive evaluations of skin based on data from biophysical in~trumentation.~~ The importance of noninvasive assessment is emphasized by a multiplicity of instrumentation that has been developed independently by investigators from around the world. Advantages of this approach include reduction of subjectivity in data c~l l e c t i o n~~~~~" and availability of instrumentation to any investigative center.
Prospective measurements from skin with available instrumentation may include the following: However, the selection and development of standards will require extensive validation and consideration of practical limitations to recommended uses of candidate instruments. For example, both the evaporimeter and the dermal phase meter measure epidermal barrier. 112 However, environmental requirements (ambient humidity, air currents) for operation of the evaporimeter make it relatively impractical for use with intensive care patients. In contrast, the dermal phase meter is not subject to these limitations and serves efficiently and conveniently in all human subject^.^^^^^^ Skin elasticity has also been measured with the cutometer to evaluate bums grafted with meshed skin graft or cultured keratinocyte sheets over dermis.lo7 Although existing instruments have been calibrated and validated for individual endpoints in narrow populations, correlation among endpoints has received only exploratory attention.l14 Validation for broad-use individual or aggregate assessments will require the following:
1. Characterization of subject variables (age, race, gender). 2. Distinction of normal and pathologic skin. Because native skin may be characterized by its individual biophysical characteristics, it may hypothetically be quantified as a composite score of multiple biophysical properties. If valid, that score should be a substitute for clinical examination. Electrocardiograms, electroencephalograms, magnetic resonance imaging, computerized axial tomography, and radiography are examples of noninvasive biophysical instruments that have provided diagnostic data beyond the perception and resolution of a clinical examination.
FUTURE DIRECTIONS
As anatomy and physiology of cultured skin substitutes improve, they will become more homologous to native skin graft. Improvement of skin substitutes will result from modifications of culture media, sub-strates, and physical environment (i.e., humidity, mechanical tension, electrical properties) that have more fidelity to native skin. Better homology may be expected to reduce stringency for clinical use of cultured skin substitutes and accomplish the efficacy of skin autograft. After predictable efficacy is shown with autologous cells, successful models will become platforms for testing of chimeric grafts and genetically modified ~e l l s .~~,~~.~~~,~~~ Gene therapy for treatment of local or systemic conditions is feasible with cultured skin substitutes.4~77~115~117-119 For wound healing applications, transient expression of selected gene products may be best, whereas constitutive gene expression may be required for systemic deficiencies. Delivery of gene products systemically probably will require physiologic regulation to be efficacious. 120 If engineering of skin and other tissues is to become a true science, members of its community must begin to think and act like engineers. Therefore, like other engineering disciplines, uniform standards for quantitative analysis of cultured skin substitutes must be established for evaluation of materials composition and performance. This goal will require interdisciplinary review and development of consensus. However, establishment of these engineering standards will provide a platform from which validation and introduction of skin and other tissue substitutes will be expedited. Although the term "tissue engineering" describes a relatively new interdisciplinary field, it has its roots many years past in the fields of cell culture and polymer c h e r n i~t r y . '~~-'~~ If past progress in engineering of cultured skin substitutes is an indication of progress ahead, it is easy to predict the reduction of medical morbidity and mortality by use of culture skin substitutes in the future.
